Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 12/2019

01-12-2019 | Antidepressant Drugs | Original Paper

Depression Prevalence, Antidepressant Treatment Status, and Association with Sustained HIV Viral Suppression Among Adults Living with HIV in Care in the United States, 2009–2014

Authors: Runa H. Gokhale, John Weiser, Patrick S. Sullivan, Qingwei Luo, Fengjue Shu, Heather Bradley

Published in: AIDS and Behavior | Issue 12/2019

Login to get access

Abstract

Previous research indicates a high burden of depression among adults living with HIV and an association between depression and poor HIV clinical outcomes. National estimates of diagnosed depression, depression treatment status, and association with HIV clinical outcomes are lacking. We used 2009–2014 data from the Medical Monitoring Project to estimate diagnosed depression, antidepressant treatment status, and associations with sustained viral suppression (all viral loads in past year < 200 copies/mL). Data were obtained through interview and medical record abstraction and were weighted to account for unequal selection probabilities and non-response. Of adults receiving HIV medical care in the U.S. and prescribed ART, 27% (95% confidence interval [CI] 25–29%) had diagnosed depression during the surveillance period; the majority (65%) were prescribed antidepressants. The percentage with sustained viral suppression was highest among those without depression (72%, CI 71–73%) and lowest among those with untreated depression (66%, CI 64–69%). Compared to those without depression, those with a depression diagnosis were less likely to achieve sustained viral suppression (aPR 0.95, CI 0.93–0.97); this association held for persons with treated depression compared to no depression (aPR 0.96, CI 0.94–0.99) and untreated depression compared to no depression (aPR 0.92, CI 0.89–0.96). The burden of depression among adults living with HIV in care is high. While in our study depression was only minimally associated with a lower prevalence of sustained viral suppression, diagnosing and treating depression in persons living with HIV remains crucial in order to improve mental health and avoid other poor health outcomes.
Literature
1.
2.
3.
4.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedPubMedCentralCrossRef
5.
Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.PubMedCrossRef
6.
May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (London, England). 2014;28(8):1193–202.PubMedPubMedCentralCrossRef
7.
Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.PubMedPubMedCentralCrossRef
8.
Do AN, Rosenberg ES, Sullivan PS, Beer L, Strine TW, Schulden JD, et al. Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS ONE. 2014;9(3):e92842.PubMedPubMedCentralCrossRef
9.
Gowda C, Coppock D, Brickman C, Shaw PA, Gross R. Determinants of HIV transmission risk among HIV-infected persons engaged in care. AIDS Educ Prev. 2016;28(5):440–52.PubMedCrossRef
10.
Simoni JM, Safren SA, Manhart LE, Lyda K, Grossman CI, Rao D, et al. Challenges in addressing depression in HIV research: assessment, cultural context, and methods. AIDS Behav. 2011;15(2):376–88.PubMedPubMedCentralCrossRef
11.
Glynn TR, Llabre MM, Lee JS, Bedoya CA, Pinkston MM, O’Cleirigh C, et al. Pathways to health: an examination of hiv-related stigma, life stressors, depression, and substance use. Int J Behav Med. 2019;26:286.PubMedCrossRefPubMedCentral
12.
Schuster R, Bornovalova M, Hunt E. The influence of depression on the progression of HIV: direct and indirect effects. Behav Modif. 2012;36(2):123–45.PubMedCrossRef
13.
Bozorgmehr A, Alizadeh F, Ofogh SN, Hamzekalayi MRA, Herati S, Moradkhani A, et al. What do the genetic association data say about the high risk of suicide in people with depression? A novel network-based approach to find common molecular basis for depression and suicidal behavior and related therapeutic targets. J Affect Disord. 2018;229:463–8.PubMedCrossRef
14.
Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients. Results from the medical outcomes study. Jama. 1989;262(7):914–9.PubMedCrossRef
15.
Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(8):807–16.PubMedCrossRef
16.
Hunter JC, DeVellis BM, Jordan JM, Sue Kirkman M, Linnan LA, Rini C, et al. The association of depression and diabetes across methods, measures, and study contexts. Clin Diabetes Endocrinol. 2018;4:1.PubMedPubMedCentralCrossRef
17.
Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American heart association. Circulation. 2014;129(12):1350–69.PubMedCrossRef
18.
Thombs BD, de Jonge P, Coyne JC, Whooley MA, Frasure-Smith N, Mitchell AJ, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA. 2008;300(18):2161–71.PubMedCrossRef
19.
Drudi LM, Ades M, Turkdogan S, Huynh C, Lauck S, Webb JG, et al. Association of depression with mortality in older adults undergoing transcatheter or surgical aortic valve replacement. JAMA Cardiology. 2018;3:191.PubMedPubMedCentralCrossRef
20.
Carrico AW, Bangsberg DR, Weiser SD, Chartier M, Dilworth SE, Riley ED. Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons. AIDS (London, England). 2011;25(8):1113–8.PubMedCentralCrossRef
21.
Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav. 2012;16(8):2119–43.PubMedPubMedCentralCrossRef
22.
Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr (1999). 2008;47(3):384–90.CrossRef
23.
Mills JC, Harman JS, Cook RL, Marlow NM, Harle CA, Duncan RP, et al. Comparative effectiveness of dual versus single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. AIDS (London, England). 2017;31(18):2515–24.PubMedCentralCrossRef
24.
25.
Centers for Disease Control and Prevention. Behavioral and clinical characteristics of persons receiving medical care for HIV infection—Medical Monitoring Project, United States, 2014 Cycle (June 2014–May 2015). 2016. Contract No.: 17.
26.
Centers for Disease Control and Prevention. Behavioral and clinical characteristics of persons receiving medical care for HIV infection—Medical Monitoring Project, United States, 2013 Cycle (June 2013–May 2014). 2016. Contract No.: 16.
27.
Centers for Disease Control and Prevention. Behavioral and clinical characteristics of persons receiving medical care for HIV infection—Medical Monitoring Project, United States, 2011. 2015. Contract No.: 10.
28.
Centers for Disease Control and Prevention. Behavioral and clinical characteristics of persons receiving medical care for HIV infection—Medical Monitoring Project, United States, 2010. 2014. Contract No.: 9.
29.
30.
Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: meta-analyses of diagnoses and symptoms. Psychol Bull. 2017;143(8):783–822.PubMedPubMedCentralCrossRef
31.
Beer L, Mattson CL, Bradley H, Skarbinski J. Understanding cross-sectional racial, ethnic, and gender disparities in antiretroviral use and viral suppression among HIV patients in the United States. Medicine. 2016;95(13):e3171.PubMedPubMedCentralCrossRef
32.
33.
Brown MA, Gellatley W, Hoffman A, Dowdell L, Camac A, Francois R, et al. Medical complications of homelessness: a neglected side of men’s health. Int Med J. 2019;49(4):455–60.CrossRef
34.
Thakarar K, Morgan JR, Gaeta JM, Hohl C, Drainoni ML. Homelessness, HIV, and incomplete viral suppression. J Health Care Poor Underserved. 2016;27(1):145–56.PubMedPubMedCentralCrossRef
35.
Park H, Song I, Shin JY. High Prevalence of depression diagnosis among medical aid beneficiaries: a Korean health insurance database study. Asia Pac J Public Health. 2017;29(8):692–7.PubMedCrossRef
36.
Ludema C, Cole SR, Eron JJ, Edmonds A, Holmes GM, Anastos K, et al. Impact of health insurance, ADAP, and income on HIV Viral suppression among US women in the women’s interagency HIV study, 2006–2009. J Acquir Immune Defic Syndr (1999). 2016;73(3):307–12.CrossRef
37.
Tolson C, Richey LE, Zhao Y, Korte JE, Brady K, Haynes L, et al. Association of substance use with hospitalization and virologic suppression in a Southern academic HIV clinic. Am J Med Sci. 2018;355(6):553–8.PubMedPubMedCentralCrossRef
38.
Sowa NA, Bengtson A, Gaynes BN, Pence BW. Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. J Affect Disord. 2016;192:153–61.PubMedCrossRef
39.
Chhim K, Mburu G, Tuot S, Sopha R, Khol V, Chhoun P, et al. Factors associated with viral non-suppression among adolescents living with HIV in Cambodia: a cross-sectional study. AIDS Res Ther. 2018;15(1):20.PubMedPubMedCentralCrossRef
40.
Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015;17(1):530.PubMedCrossRef
41.
Mayston R, Kinyanda E, Chishinga N, Prince M, Patel V. Mental disorder and the outcome of HIV/AIDS in low-income and middle-income countries: a systematic review. AIDS (London, England). 2012;26(Suppl 2):S117–35.CrossRef
42.
Mitchell AJ, Lord O, Malone D. Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis. Br J Psychiatry. 2012;201(6):435–43.PubMedCrossRef
43.
Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr (1999). 2011;58(2):181–7.CrossRef
44.
Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, et al. Recommendations for HIV prevention with adults and adolescents with HIV in the United States. 2014.
45.
Yager J, Faragon J, McGuey L, Hoye-Simek A, Hecox Z, Sullivan S, et al. Relationship between single tablet antiretroviral regimen and adherence to antiretroviral and non-antiretroviral medications among Veterans’ affairs patients with human immunodeficiency virus. AIDS Patient Care STDs. 2017;31(9):370–6.PubMedCrossRef
46.
Truong WR, Schafer JJ, Short WR. Once-daily, single-tablet regimens for the treatment of HIV-1 infection. Pharm Therapeutics. 2015;40(1):44–55.
47.
Beer L, Mattson CL, Bradley H, Shouse RL. Trends in ART prescription and viral suppression among HIV-positive young adults in care in the United States, 2009–2013. J Acquir Immune Defic Syndr (1999). 2017;76(1):e1–6.CrossRef
48.
Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27(23):2763–74.PubMedCrossRef
49.
Barefoot JC, Helms MJ, Mark DB, Blumenthal JA, Califf RM, Haney TL, et al. Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol. 1996;78(6):613–7.PubMedCrossRef
50.
Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010;170(21):1884–91.PubMedPubMedCentralCrossRef
51.
Moise N, Khodneva Y, Jannat-Khah DP, Richman J, Davidson KW, Kronish IM, et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: the REGARDS study. BMJ Open. 2018;8(1):e017385.PubMedPubMedCentralCrossRef
52.
Feigin V. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1545–602.CrossRef
53.
Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016;3(5):415–24.PubMedCrossRef
54.
Mayer KH, Loo S, Crawford PM, Crane HM, Leo M, DenOuden P, et al. Excess clinical comorbidity among HIV-infected patients accessing primary care in US community health centers. Public Health Rep. 2018;133(1):109–18.PubMedCrossRef
55.
Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, et al. Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population. J Acquir Immune Defic Syndr. (1999). 2017;75(5):568–76.CrossRef
56.
Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York city. Ann Intern Med. 2006;145(6):397–406.PubMedCrossRef
57.
58.
American Psychiatric Association. Practice guideline for the treatment of patients with HIV/AIDS. 2000.
Metadata
Title
Depression Prevalence, Antidepressant Treatment Status, and Association with Sustained HIV Viral Suppression Among Adults Living with HIV in Care in the United States, 2009–2014
Authors
Runa H. Gokhale
John Weiser
Patrick S. Sullivan
Qingwei Luo
Fengjue Shu
Heather Bradley
Publication date
01-12-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 12/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02613-6

Other articles of this Issue 12/2019

AIDS and Behavior 12/2019 Go to the issue

Original Paper

Yes to Recreational Drugs and Complementary Medicines But No to Life-Saving Medications: Beliefs Underpinning Treatment Decisions Among PLHIV

Original Paper

A Dyadic Investigation of Relationship Dynamics and Depressive Symptoms in HIV-Affected Couples in Malawi

Original Paper

Suicidal Ideation Among Adults Re-engaging in HIV Care in Argentina

Original Paper

Distinct Profiles of Consumers of Psychoactive Substances in People Attending French Sexual Transmitted Infections Centers

Original Paper

Characteristics of Persons Who Inject Drugs with Recent HIV Infection in the United States: National HIV Behavioral Surveillance, 2012

Original Paper

Alcohol, But Not Depression or IPV, Reduces HIV Adherence Among South African Mothers Living with HIV Over 5 Years

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits